Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria

Blood

Volumn 116, Issue 7, 2010, Pages 1051-1055

  Carobbio, Alessandra ^a   Finazzi, Guido ^a   Antonioli, Elisabetta ^b   Vannucchi, Alessandro M ^b   Barosi, Giovanni ^c   Ruggeri, Marco ^d   Rodeghiero, Francesco ^d   Delaini, Federica ^a   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; PLATELET COUNT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956553291     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-272179     Document Type: Article

References (12)

1. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
2. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
3. Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost. 2009;7(9):1587-1589.
4. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310-2313. (Pubitemid 46425868)
5. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446-2452. (Pubitemid 46425887)
6. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759-763.
7. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991-2999.
8. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;129(4):409-417.
9. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833.
10. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953. (Pubitemid 41713984)
11. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-530. (Pubitemid 40592168)
12. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061-4068.